Connecticut et al v. Sandoz, Inc. et al
Case Number:
3:20-cv-00802
Court:
Nature of Suit:
Judge:
Firms
- Armstrong Teasdale
- Arnold & Porter
- Bailey Duquette
- Baker Botts
- Barnes & Thornburg
- Clifford Chance
- Cole Schotz
- Competition Law Partners
- Day Pitney
- Debevoise & Plimpton
- Dechert LLP
- Dentons
- DLA Piper
- Faegre Drinker
- Fine Kaplan
- Harris Beach Murtha Cullina PLLC
- Hinckley Allen
- Hogan Lovells
- Kasowitz LLP
- Kelley Drye
- K&L Gates
- Linklaters LLP
- Mintz Levin
- Morgan Lewis
- Morrison & Foerster
- Norton Rose
- O'Toole & O'Toole
- Paul Hastings
- Petrillo Klein
- Proskauer Rose
- Reed Smith
- Ropes & Gray
- Saul Ewing
- Saxton & Stump
- Shapiro Arato
- Skadden Arps
- Sperling Kenny
- Troutman
- Wiggin & Dana
- Wilson Sonsini
Companies
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Aurobindo Pharma Ltd.
- Bausch Health Cos. Inc.
- Cencora Inc.
- Fougera Pharmaceuticals Inc.
- Glenmark Pharmaceuticals Ltd.
- G&W Laboratories Inc.
- Lannett Company, Inc
- Lupin Ltd.
- Mallinckrodt PLC
- Optum Inc.
- OptumRx Inc.
- Perrigo Co. PLC
- Pfizer Inc.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Wockhardt USA LLC
Government Agencies
- Commonwealth of Kentucky
- Commonwealth of Massachusetts
- State of Indiana
- State of Michigan
- State of Nevada
- State of Tennessee
- U.S. District Court for the District of Columbia
Sectors & Industries:
-
April 09, 2026
Irish Mallinckrodt Unit Stuck In Drug Price-Fixing Suit
An Irish entity of drugmaker Mallinckrodt waited too long to seek dismissal of a price-fixing lawsuit brought by states based on a lack of personal jurisdiction or proper service, a Connecticut federal judge has ruled, finding that the company first raised that argument more than five years after the complaint was filed.
-
April 08, 2026
States Seek Time For Talks To Settle Drug Price-Fixing Suit
The states suing generic-drug manufacturers in one of three sprawling antitrust cases want a Connecticut federal judge to pause all deadlines for three months so they can focus on settling with the remaining defendants, according to a joint filing.
-
March 04, 2026
Buyers Finalize $58M Generic-Pricing Deal With 3 Drugmakers
Purchasers of certain generic drugs asked a Pennsylvania federal court for final approval of settlements worth a total of at least $58 million with Glenmark Pharmaceutical Inc., Greenstone LLC and Pfizer Inc. over claims the companies colluded with others to keep drug prices high.
-
March 02, 2026
PosiGen Can Wind Down, Tilson's Ch. 11 Dismissed
Solar panel co. PosiGen was given the green light to wind down, fiber network Tilson's Chapter 11 case was dismissed, and Mallinckrodt's bankruptcy prevented antitrust payouts.
-
February 26, 2026
$200M Antitrust Deal Can Shield Drugmakers In States' Claims
Sun Pharmaceutical and Taro Pharmaceuticals can use their $200 million settlement with the "end payors" for generic drugs in an alleged price-fixing scheme as a defense in a similar lawsuit brought by 47 states and territories, the Connecticut federal judge overseeing the case ruled Wednesday.
-
February 25, 2026
$17.9M Drug Price-Fixing Deal Advances Despite Objections
A Connecticut federal judge on Wednesday advanced a $17.9 million generic drug price-fixing settlement between 48 states and territories and pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc. and Lannett Co. Inc., sidelining objections by consumers suing separately in a Pennsylvania multidistrict litigation case.
-
February 24, 2026
Mallinckrodt's Ch. 11 Blocks Antitrust Payouts, Judge Rules
A Connecticut federal judge has ruled that drugmaker Mallinckrodt PLC shrugged off monetary claims brought by states in a sprawling generic drug antitrust enforcement action when the company emerged from bankruptcy in 2022.
-
February 19, 2026
Judge Denies Mylan And Aurobindo's Bid To Escape Trial
A Connecticut federal judge has once again rejected generic-drug makers' bid to escape a multistate lawsuit accusing them of engaging in an overarching antitrust conspiracy, saying the evidence supports the need for a jury trial on whether the companies colluded to fix prices and divvy up markets for dozens of generic drugs.
-
February 17, 2026
Judge Rips Drugmakers' Borderline 'Disingenuous' Appeal Bid
A Connecticut federal judge has rejected generic-drug makers' request for a quick appeal of his ruling denying them summary judgment on states' claims they engaged in an "overarching conspiracy" to fix prices, slamming the request for being borderline "disingenuous," mischaracterizing his reasoning and ignoring direct evidence of alleged wrongdoing.
-
February 13, 2026
States' Generic Drugs Antitrust Case Headed Toward Trial
A Connecticut federal judge has mostly refused to side with pharmaceutical companies facing states' generic drug price-fixing litigation against them, ruling that there are genuine disputes of material fact as to drug distribution chains and the states' antitrust standing and teeing up the case for trial.